Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-1496 · 1 trial · 2 indications
Dose-limiting toxicities (DLTs) are any adverse events that are not clearly related to disease progression including Grade 4 neutropenia, Grade 3 or 4 febrile neutropenia, thrombocytopenic bleeding or Grade 4 thrombocytopenia, and any Grade 3 or 4 non hematologic toxicity. An adverse event (AE) is any unfavorable and unintended change in the structure and function (Clinical AE) or chemistry (Laboratory AE) of the body temporally associated with the use of study product, whether or not considered related to the use of the product.
This is a measure of the number of participants who experienced any adverse event (AE) while on study.
| Arm | Type | Description |
|---|---|---|
| MK-1496 20 mg (21-Day Cycle) | EXPERIMENTAL | Participants receiving MK-1496 20 mg on Day 1 of each 21-day cycle |
| MK-1496 40 mg (21-Day Cycle) | EXPERIMENTAL | Participants receiving MK-1496 40 mg on Day 1 of each 21-day cycle |
| MK-1496 80 mg (21-Day Cycle) | EXPERIMENTAL | Participants receiving MK-1496 80 mg on Day 1 of each 21-day cycle |
| MK-1496 120 mg (21-Day Cycle) | EXPERIMENTAL | Participants receiving MK-1496 120 mg on Day 1 of each 21-day cycle |
| MK-1496 20 mg (28-Day Cycle) | EXPERIMENTAL | Participants receiving MK-1496 20 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle |
| MK-1496 40 mg (28-Day Cycle) | EXPERIMENTAL | Participants receiving MK-1496 40 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle |
| MK-1496 80 mg (28-Day Cycle) | EXPERIMENTAL | Participants receiving MK-1496 80 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle |
| MK-1496 100 mg (28-Day Cycle) | EXPERIMENTAL | Participants receiving MK-1496 100 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle |
| MK-1496 120 mg (28-Day Cycle) | EXPERIMENTAL | Participants receiving MK-1496 120 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle |
| Name | Type | Description |
|---|---|---|
| MK-1496 | DRUG | MK-1496 (20 to 120 mg), orally, administered on Day 1 of each 21-day cycle |
Inclusion Criteria * Participant must have a histologically-confirmed metastatic or locally advanced solid tumor that has failed to respond to standard therapy, progressed despite standard therapy, or for which standard therapy does not exist. * Participant must have Performance Status 0 or 1. * Pa...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
MK-1496 is an investigational small molecule being studied for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is being developed by Merck & Company, Inc. for use in oncology, specifically targeting malignant neoplasms, which are cancers.
MK-1496 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. Merck is conducting clinical research to evaluate the safety and efficacy of this investigational oncology drug.
MK-1496 is in Phase 1 clinical development. It has completed one Phase 1 trial, which was a study in patients with advanced solid tumors. As an investigational drug, it is not yet approved by regulatory authorities and remains in clinical testing.
MK-1496 has one completed clinical trial registered as NCT00880568. This was a Phase 1 study in patients with advanced solid tumors, enrolling 27 participants aged 18 years and older. The trial was controlled but not randomized or double-blinded, and it has been completed.
MK-1496 is a small molecule, but its specific molecular target has not been disclosed in available information. As an investigational oncology drug, it is being studied for its potential to treat malignant neoplasms, though the exact mechanism of action is not publicly detailed.